Qiang Ding

US Patent:

7176312, Feb 13, 2007

Filed:

Oct 12, 2002

Appl. No.:

10/270030

Inventors:

Sheng Ding - San Diego CA, US
Qiang Ding - San Diego CA, US
Nathanael S. Gray - San Diego CA, US

Assignee:

The Scripps Research Institute - La Jolla CA
IRM LLC

International Classification:

C07D 473/16
C07D 487/04
C07D 239/94
C07D 401/14
C07D 403/12

US Classification:

544277, 544264, 544276, 544265, 544224, 544237, 544239, 544336, 544408, 544316, 544320, 544322, 544323, 544326, 544330, 544286, 544287, 544291, 544292, 544293, 544353, 544354, 546304, 546307, 546312, 546153, 546159, 546160, 546171, 435 4, 548557, 548558, 548559, 548469, 548483, 548484, 5483064, 5483074, 5483077, 5483081

Abstract:

General methods for the solution phase as well as solid phase synthesis of various substituted heteroaryls has been demonstrated. These substituted heteroaryls can be further elaborated by aromatic substitution with amines at elevated temperature or by anilines, boronic acids and phenols via palladium catalyzed cross-coupling reactions.

US Patent:

7338957, Mar 4, 2008

Filed:

Aug 26, 2004

Appl. No.:

10/927992

Inventors:

Qiang Ding - San Diego CA, US
Nathanael Schiander Gray - San Diego CA, US
Bing Li - San Diego CA, US
Yi Liu - San Diego CA, US
Tetsuo Uno - San Diego CA, US

Assignee:

IRM LLC - Hamilton

International Classification:

C07D 487/04
A61K 31/519
A61P 35/00

US Classification:

5142651, 544280

Abstract:

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, SAPK2α and SAPK2β kinases.

US Patent:

7371750, May 13, 2008

Filed:

Jul 29, 2004

Appl. No.:

10/909227

Inventors:

Taebo Sim - San Diego CA, US
Hyun Soo Lee - San Diego CA, US
Pingda Ren - San Diego CA, US
Qiang Ding - San Diego CA, US
Guobao Zhang - San Diego CA, US
Yi Liu - San Diego CA, US
Xia Wang - San Diego CA, US
Tetsuo Uno - San Diego CA, US
Bing Li - San Diego CA, US
Lintong Li - San Diego CA, US
Nathanael Schiander Gray - San Diego CA, US
Shuli You - San Diego CA, US

Assignee:

IRM LLC - Hamilton

International Classification:

A61K 31/5355
A61K 31/53
A61K 31/497
A61K 31/513
C07D 413/12
C07D 253/065
C07D 487/04
C07D 413/14
A61P 35/00
C07D 471/04

US Classification:

5142342, 514242, 51425216, 5142621, 544112, 544118, 544182, 544256, 544279, 544 81

Abstract:

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases.

US Patent:

7449582, Nov 11, 2008

Filed:

Oct 8, 2004

Appl. No.:

10/961646

Inventors:

Qiang Ding - San Diego CA, US
Yongping Xie - San Diego CA, US
Nathanael S. Gray - San Diego CA, US
Shuli You - San Diego CA, US
Greg Chopiuk - San Diego CA, US
Jiqing Jiang - San Diego CA, US
Yi Liu - San Diego CA, US
Ruo Steensma - La Jolla CA, US
Xing Wang - San Diego CA, US
Taebo Sim - San Diego CA, US

Assignee:

IRM LLC - Hamilton

International Classification:

C07D 215/38
C07D 471/02
C07D 251/38

US Classification:

546153, 546157, 546123, 544224, 5142641, 514299

Abstract:

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGFβ, SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2β kinases.

US Patent:

7642255, Jan 5, 2010

Filed:

Apr 8, 2008

Appl. No.:

12/099708

Inventors:

Taebo Sim - Seoul, KR
Hyun Soo Lee - San Diego CA, US
Pingda Ren - San Diego CA, US
Qiang Ding - San Diego CA, US
Yi Liu - San Diego CA, US
Bing Li - Westborough MA, US
Lintong Li - San Diego CA, US
Xia Wang - San Diego CA, US
Tetsuo Uno - San Diego CA, US
Guobao Zhang - San Diego CA, US
Nathanael Schiander Gray - Boston MA, US
Shuli You - Shanghai, CN

Assignee:

IRM LLC - Hamilton

International Classification:

C07D 413/14
C07D 471/04
C07D 487/04
A61K 31/535
A61K 31/497
A61K 31/519
C07D 251/12
A61K 31/53
A61P 35/00

US Classification:

5142342, 514241, 51425505, 51425216, 5142641, 51425214, 5142621, 544279, 544117, 544215, 544256, 544118

Abstract:

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases.

US Patent:

7745437, Jun 29, 2010

Filed:

Jun 9, 2005

Appl. No.:

11/628881

Inventors:

Pingda Ren - San Diego CA, US
Xia Wang - San Diego CA, US
Guobao Zhang - San Diego CA, US
Qiang Ding - San Diego CA, US
Shuli You - Shanghai, CN
Qiong Zhang - San Diego CA, US
Greg Chopiuk - San Diego CA, US
Pamela A. Albaugh - Carlsbad CA, US
Taebo Sim - San Diego CA, US
Nathanael Schiander Gray - Boston MA, US

Assignee:

IRM LLC - Hamilton

International Classification:

C07D 403/04
A61K 31/4178

US Classification:

5142358, 514249, 51425202, 51425405, 514256, 544122, 544238, 544295, 544328

Abstract:

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, ΣΓK, Tιε2, Λχκ, θNK2α2, MKK4, c-RAF, MKK6, SAPK2α and SAPK2β kinases.

US Patent:

7893074, Feb 22, 2011

Filed:

Aug 13, 2004

Appl. No.:

10/568367

Inventors:

Carlos Garcia-Echeverria - Basel, CH
Takanori Kanazawa - Tsukuba, JP
Eiji Kawahara - Tsukuba, JP
Keiichi Masuya - Tsukuba, JP
Naoko Matsuura - Tsukuba, JP
Takahiro Miyake - Tsukuba, JP
Osamu Ohmori - Tsukuba, JP
Ichiro Umemura - Tsukuba, JP
Ruo Steensma - La Jolla CA, US
Greg Chopiuk - San Diego CA, US
Jiqing Jiang - San Diego CA, US
Yongqin Wan - Irvine CA, US
Qiang Ding - San Diego CA, US
Qiong Zhang - San Diego CA, US
Nathanael Schiander Gray - San Diego CA, US
Donald Karanewsky - Escondido CA, US

Assignee:

Novartis AG - Basel
IRM LLC - Hamilton

International Classification:

C07D 239/48
A61K 31/506

US Classification:

514275, 544323

Abstract:

Novel pyrimidine derivatives of formula I.

US Patent:

8202876, Jun 19, 2012

Filed:

Sep 24, 2007

Appl. No.:

12/444129

Inventors:

Pamela Albaugh - Carlsbad CA, US
Gregory B. Chopiuk - San Diego CA, US
Qiang Ding - San Diego CA, US
Shenlin Huang - San Diego CA, US
Zuosheng Liu - San Diego CA, US
Shifeng Pan - San Diego CA, US
Pingda Ren - San Diego CA, US
Xia Wang - San Diego CA, US
Xing Wang - San Diego CA, US
Yongping Xie - San Diego CA, US
Chengzhi Zhang - San Diego CA, US
Qiong Zhang - Union City CA, US
Guobao Zhang - San Diego CA, US
Daniel Poon - Oakland CA, US
Paul Renhowe - Danville CA, US
Martin Sendzik - San Mateo CA, US

Assignee:

IRM LLC - Hamilton
Novartis AG - Basel

International Classification:

C07D 401/00
C07D 403/00
C07D 405/00
C07D 409/00
C07D 411/00
C07D 413/00
C07D 417/00
C07D 419/00
C07D 231/00
C07D 403/02
A01N 43/56
A61K 31/415

US Classification:

514256, 514406, 544333, 5483641

Abstract:

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases.